Voyager Therapeutics, Inc.
VYGR
$4.15
$0.030.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -59.94% | 144.28% | -45.73% | -82.42% | -66.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -59.94% | 144.28% | -45.73% | -82.42% | -66.83% |
| Cost of Revenue | -21.96% | -5.71% | 18.60% | -1.95% | 16.37% |
| Gross Profit | 12.15% | 37.84% | -300.94% | -1,000.67% | -230.69% |
| SG&A Expenses | -14.30% | -8.65% | -0.92% | 3.39% | 12.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.17% | -6.30% | 14.45% | -0.66% | 15.31% |
| Operating Income | 12.75% | 30.99% | -122.02% | -192.42% | -114.38% |
| Income Before Tax | 9.88% | 19.13% | -208.95% | -229.81% | -173.81% |
| Income Tax Expenses | -62.16% | -98.46% | 93.02% | -37.50% | 164.29% |
| Earnings from Continuing Operations | 9.94% | 20.47% | -208.40% | -229.18% | -173.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.94% | 20.47% | -208.40% | -229.18% | -173.80% |
| EBIT | 12.75% | 30.99% | -122.02% | -192.42% | -114.38% |
| EBITDA | 12.89% | 31.93% | -134.52% | -219.41% | -124.72% |
| EPS Basic | 11.66% | 21.79% | -203.45% | -223.85% | -167.94% |
| Normalized Basic EPS | 11.63% | 30.62% | -204.12% | -330.91% | -168.09% |
| EPS Diluted | 11.66% | 21.34% | -196.44% | -216.67% | -165.80% |
| Normalized Diluted EPS | 11.63% | 30.62% | -204.12% | -330.91% | -168.09% |
| Average Basic Shares Outstanding | 1.96% | 1.66% | 1.65% | 1.64% | 2.16% |
| Average Diluted Shares Outstanding | 1.96% | 1.66% | 1.65% | 1.64% | 2.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |